[
  {
    "ts": "2026-01-05T02:11:14+00:00",
    "headline": "Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound",
    "summary": "Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...",
    "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-modest-021114654.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "713d8659-f86f-3e1c-869b-d0977f5d29e8",
      "content": {
        "id": "713d8659-f86f-3e1c-869b-d0977f5d29e8",
        "contentType": "STORY",
        "title": "Moderna (MRNA): Reassessing Valuation After a Modest Share Price Rebound",
        "description": "",
        "summary": "Moderna (MRNA) has been quietly grinding higher, with the stock up roughly 11% over the past month and 12% in the past 3 months, even as its one year return remains negative. See our latest analysis for Moderna. That recent 11% 1 month share price return looks more like early momentum than a full turnaround, especially when set against Moderna’s 1 year total shareholder return of negative 26.8% and deeply negative multi year performance. If Moderna’s move has you rethinking healthcare...",
        "pubDate": "2026-01-05T02:11:14Z",
        "displayTime": "2026-01-05T02:11:14Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lV6Oo0M_C3X63uXoBkpnwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KdbFtaQiMRVA6Enl712wNA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/759f0ca28b885d5d534769cdaccce534.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-modest-021114654.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-mrna-reassessing-valuation-modest-021114654.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T12:00:00+00:00",
    "headline": "Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine",
    "summary": "Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational ...",
    "url": "https://finance.yahoo.com/news/moderna-announces-global-regulatory-submissions-120000895.html",
    "source": "ACCESS Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "cdd5803b-f68f-30aa-a4f1-33063cca9623",
      "content": {
        "id": "cdd5803b-f68f-30aa-a4f1-33063cca9623",
        "contentType": "STORY",
        "title": "Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine",
        "description": "",
        "summary": "Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an update on regulatory submissions for its investigational ...",
        "pubDate": "2026-01-05T12:00:00Z",
        "displayTime": "2026-01-05T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "<![CDATA[Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire ...]]>",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y14NrymWnVHtLPxT5mPm5g--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dSewxxG3XkMHQTa3gmVr6w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/2233b456baebcb9b5dcb57d6eaa868ac.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "ACCESS Newswire",
          "url": "https://www.accessnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/moderna-announces-global-regulatory-submissions-120000895.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-announces-global-regulatory-submissions-120000895.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-05T11:44:00+00:00",
    "headline": "Moderna, searching for a rebound, to seek approval of mRNA flu shot",
    "summary": "The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.",
    "url": "https://www.biopharmadive.com/news/moderna-file-approval-mrna-flu-vaccine/808706/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "de408d6a-69db-3d87-bc5a-7762acd6956f",
      "content": {
        "id": "de408d6a-69db-3d87-bc5a-7762acd6956f",
        "contentType": "STORY",
        "title": "Moderna, searching for a rebound, to seek approval of mRNA flu shot",
        "description": "",
        "summary": "The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.",
        "pubDate": "2026-01-05T11:44:00Z",
        "displayTime": "2026-01-05T11:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/6f1aeaf3c7b754444446c9ea87957a57",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "The Moderna headquarters is seen on November 30, 2020 in Cambridge, Massachusetts.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lkx01CaP1sQh8nzs.uZmqQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/6f1aeaf3c7b754444446c9ea87957a57.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/G5ki8L6F4.VmKiLOMdWvgg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/6f1aeaf3c7b754444446c9ea87957a57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/moderna-file-approval-mrna-flu-vaccine/808706/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/moderna-searching-rebound-seek-approval-114400311.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRNA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]